Anaplastic lymphoma kinase inhibitors—a review of anticancer properties, clinical efficacy, and resistance mechanisms
K Kiełbowski, J Żychowska, R Becht - Frontiers in Pharmacology, 2023 - frontiersin.org
Fusions and mutations of anaplastic lymphoma kinase (ALK), a tyrosine kinase receptor,
have been identified in several neoplastic diseases. Rearranged ALK is a driver of …
have been identified in several neoplastic diseases. Rearranged ALK is a driver of …
Real‐world evidence of brigatinib as second‐line treatment after crizotinib for ALK+ non‐small cell lung cancer using South Korean claims data (K‐AREAL)
Purpose There is a lack of real‐world data in Asian populations for brigatinib, a next‐
generation anaplastic lymphoma kinase (ALK) inhibitor for patients with non‐small cell lung …
generation anaplastic lymphoma kinase (ALK) inhibitor for patients with non‐small cell lung …
Bridging the Gap between Trial Adverse Events and Real-World Data
We congratulate Jeon et al.[1] for their thorough analysis comparing alectinib and brigatinib
as first-line therapies for advanced non–small cell lung cancer (NSCLC) with anaplastic …
as first-line therapies for advanced non–small cell lung cancer (NSCLC) with anaplastic …
[PDF][PDF] Correspondence: Dong Won Park
SH Kim, H Lee - scholar.archive.org
We congratulate Jeon et al.[1] for their thorough analysis comparing alectinib and brigatinib
as first-line therapies for advanced non-small cell lung cancer (NSCLC) with anaplastic …
as first-line therapies for advanced non-small cell lung cancer (NSCLC) with anaplastic …